Paul Burke is Principal of Burke Bioventures LLC, a biotechnology consultancy providing strategic advice and scientific direction for biotechnology, pharmaceutical, and drug delivery companies, with a particular focus on nanotechnology, targeting, and RNA. Dr. Burke brings two decades of biopharmaceutical industry experience, having served in executive roles at Amgen, Merck, and Pfizer where he specialized in launching and directing new technology initiatives for transforming discovery and preclinical pipelines. He received his PhD in Biological Chemistry from the Massachusetts Institute of Technology, Cambridge, USA, and is Affiliate Professor of Bioengineering, University of Washington, Seattle, and, for the winter 2017 term, was the Distinguished Visiting Professor at City of Hope’s Beckman Research Institute